The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Progression-free survival (PFS)
Timeframe: From the first line treatment up to the end of the study period (April 2019).
Overall survival (OS)
Timeframe: From the diagnosis up to the end of the study period (April 2019).
Response to treatment
Timeframe: From the first line treatment up to the end of the study period (April 2019).
Event-free survival (EFS)
Timeframe: From the first line treatment up to the end of the study period (April 2019).